Matches in SemOpenAlex for { <https://semopenalex.org/work/W166758097> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W166758097 endingPage "10" @default.
- W166758097 startingPage "5" @default.
- W166758097 abstract "To report the effect of an intravitreal injection of 4 mg of crystalline triamcinolone acetonide (Kenacort) as symptomatic treatment of neovascular glaucoma.This clinical study is based on clinical and experimental investigations that examined the tolerability and the angiostatic effect of triamcinolone acetonide. The study includes prospectively 8 eyes of 8 patients with neovascular glaucoma secondary to ischemic central retinal vein occlusion (n=8). All patients received an intravitreal injection of 4 mg of crystalline triamcinolone acetonide (0.1 cc) as the only procedure or in combination with transscleral cyclodiode as glaucoma treatment. Their mean age was 74.5 +/- 14.4 years. Mean intraocular pressure (IOP) was 38.9 +/- 9.3 mmHg. Mean follow-up was 6 months.4 of 8 patients were treated by crystalline triamcinolone acetonide as the only procedure (n=3). Twenty seven days after intravitreal kenacort injection, the others four patients have been treated by transscleral cyclodiode (n=4) as glaucoma treatment. After injection, including the first postoperative day, patients report a subjective reduction of ocular pain. Furthermore no intra- or extraocular inflammatory reactions were observed during the follow-up. Intraocular pressure was significantly reduced to 18 +/- 6.2 mm Hg at the end of the follow-up period. When considering only the four patients in which the intraocular cortisone injection was the only procedure performed, mean intraocular pressure decreased from 41.75 +/- 7.05 mm Hg to 20.5 +/- 6.6 mm Hg. Iris neovascularisation was significantly decreased from grade IV to grade I in all patients at the end of the follow-upIntravitreal injection of 4 mg triamcinolone acetonide contributes to a better management of the neovascular glaucoma." @default.
- W166758097 created "2016-06-24" @default.
- W166758097 creator A5059045881 @default.
- W166758097 creator A5061194768 @default.
- W166758097 creator A5074425069 @default.
- W166758097 creator A5074645918 @default.
- W166758097 date "2005-01-01" @default.
- W166758097 modified "2023-09-27" @default.
- W166758097 title "[Low dose intravitreal triamcinolone acetonide in the treatment of neovasular glaucoma]." @default.
- W166758097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16422216" @default.
- W166758097 hasPublicationYear "2005" @default.
- W166758097 type Work @default.
- W166758097 sameAs 166758097 @default.
- W166758097 citedByCount "3" @default.
- W166758097 countsByYear W1667580972012 @default.
- W166758097 countsByYear W1667580972015 @default.
- W166758097 crossrefType "journal-article" @default.
- W166758097 hasAuthorship W166758097A5059045881 @default.
- W166758097 hasAuthorship W166758097A5061194768 @default.
- W166758097 hasAuthorship W166758097A5074425069 @default.
- W166758097 hasAuthorship W166758097A5074645918 @default.
- W166758097 hasConcept C118487528 @default.
- W166758097 hasConcept C126322002 @default.
- W166758097 hasConcept C197934379 @default.
- W166758097 hasConcept C2776251621 @default.
- W166758097 hasConcept C2776521421 @default.
- W166758097 hasConcept C2778375690 @default.
- W166758097 hasConcept C2778527774 @default.
- W166758097 hasConcept C2778844676 @default.
- W166758097 hasConcept C2778903070 @default.
- W166758097 hasConcept C2780347916 @default.
- W166758097 hasConcept C2780827179 @default.
- W166758097 hasConcept C2781092963 @default.
- W166758097 hasConcept C42219234 @default.
- W166758097 hasConcept C71924100 @default.
- W166758097 hasConceptScore W166758097C118487528 @default.
- W166758097 hasConceptScore W166758097C126322002 @default.
- W166758097 hasConceptScore W166758097C197934379 @default.
- W166758097 hasConceptScore W166758097C2776251621 @default.
- W166758097 hasConceptScore W166758097C2776521421 @default.
- W166758097 hasConceptScore W166758097C2778375690 @default.
- W166758097 hasConceptScore W166758097C2778527774 @default.
- W166758097 hasConceptScore W166758097C2778844676 @default.
- W166758097 hasConceptScore W166758097C2778903070 @default.
- W166758097 hasConceptScore W166758097C2780347916 @default.
- W166758097 hasConceptScore W166758097C2780827179 @default.
- W166758097 hasConceptScore W166758097C2781092963 @default.
- W166758097 hasConceptScore W166758097C42219234 @default.
- W166758097 hasConceptScore W166758097C71924100 @default.
- W166758097 hasIssue "298" @default.
- W166758097 hasLocation W1667580971 @default.
- W166758097 hasOpenAccess W166758097 @default.
- W166758097 hasPrimaryLocation W1667580971 @default.
- W166758097 hasRelatedWork W1991769640 @default.
- W166758097 hasRelatedWork W1997013893 @default.
- W166758097 hasRelatedWork W2014695654 @default.
- W166758097 hasRelatedWork W2044001388 @default.
- W166758097 hasRelatedWork W2055216090 @default.
- W166758097 hasRelatedWork W2080267671 @default.
- W166758097 hasRelatedWork W2093496049 @default.
- W166758097 hasRelatedWork W2165844053 @default.
- W166758097 hasRelatedWork W2287479431 @default.
- W166758097 hasRelatedWork W2312690398 @default.
- W166758097 hasRelatedWork W2381164355 @default.
- W166758097 hasRelatedWork W2394799490 @default.
- W166758097 hasRelatedWork W2400029062 @default.
- W166758097 hasRelatedWork W2403001338 @default.
- W166758097 hasRelatedWork W2563002153 @default.
- W166758097 hasRelatedWork W2774182591 @default.
- W166758097 hasRelatedWork W2889464891 @default.
- W166758097 hasRelatedWork W2922370140 @default.
- W166758097 hasRelatedWork W3197759173 @default.
- W166758097 hasRelatedWork W3655396 @default.
- W166758097 isParatext "false" @default.
- W166758097 isRetracted "false" @default.
- W166758097 magId "166758097" @default.
- W166758097 workType "article" @default.